anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Letrozole
Trial phase: Phase 2
ATC code: L02BG04
SMILES: N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 9
Group description: Letrozole: 2.5 mg daily for twelve months
Eligibility criteria:
Inclusion Criteria:

Definite diagnosis of based on compatible chest CT and at least one of the following:

biopsy or cytology consistent with LAM, or
tuberous sclerosis, renal angiomyolipoma, cystic abdominal lymphangiomas, or chylous effusion in the chest or abdomen, or
serum VEGF-D ≥ 800 pg/uL.
post bronchodilator FEV1 ≤80% predicted or DLCO ≤70% predicted or RV≥120% predicted

female and postmenopausal status as defined by one of the following:

prior bilateral oophorectomy or bilateral ovarian irradiation, or
age greater than 55 years, and no menstrual period for 12 months or longer.

age 18-55 years and estradiol level in the postmenopausal range in the absence of current use of progestational agents.

If still premenopausal, may enter if rendered medically postmenopausal on clinical grounds with the use of gonadotropin releasing hormone (e.g. leuprolide), as long as serum estradiol, FSH, and LH are in the postmenopausal range
Patients with osteopenia or osteoporosis must be receiving appropriate treatment for their osteoporosis or osteopenia at entry into this study.

Exclusion Criteria:

Known allergy to letrozole
Inability to comply with pulmonary function tests or follow up visits.
Treatment with investigational agents within 30 days
Hormonal therapy (e.g. estrogen, progestin, LHRH agonists or antagonists, estrogen receptor blockers, estrogen receptor down regulators, aromatase inhibitors) within 30 days month of registration
Medical or psychiatric conditions that would interfere with the ability to provide informed consent.
abnormal hematologic and hepatic function as defined by the following at the time of randomization.:
Neutrophils < 1500/mm3 and platelets < 100,000/mm3
Bilirubin < 1.25 X upper limit of normal
SGPT (ALT) or SGOT (AST) >2.5 X upper limit of normal
Intervention: Ofloxacin
Trial phase: Phase 4
ATC code: A02BD10 | J01MA01 | J01MA12 | J01RA05 | J01RA09 | S01AE01 | S01AE05 | S02AA16
SMILES: CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 76
Group description: Levofloxacin: 500mg, PO, once daily for 3 months
Eligibility criteria:
Inclusion Criteria:

a primary or repeat kidney transplant recipient (deceased or living donor)
age greater or equal to 18 years

Exclusion Criteria:

Unable to provide informed consent
Greater than 5 days post-transplantation
BK virus nephropathy with a previous transplant
History of allergic reaction to any quinolone antibiotic
History of quinolone associated tendonitis or tendon rupture
Corrected QT interval prolongation on EKG as defined by Al-Khatib
Concomitant use of medication known to prolong the QT interval such as class IA antiarrhythmic drugs (e.g. quinidine, procainamide, disopyramide), class III antiarrhythmic drugs (e.g. amiodarone, sotalol), azole antifungals (e.g. fluconazole) or macrolide antibiotics (e.g. erythromycin)
Pregnant or breastfeeding as safety of levofloxacin not established
Requires quinolone antibiotic for more than 14 days (e.g. for UTI prophylaxis)
Recipient of a multi-organ transplant (e.g. kidney-pancreas)
Currently enrolled in another interventional trial
Previously enrolled in this study
History of rhabdomyolysis
Significant allergic reaction to ≥ 3 classes of antibiotics as these patients may have no other option other than quinolones for routine infection.
Intervention: Ofloxacin
Trial phase: Phase 4
ATC code: A02BD10 | J01MA01 | J01MA12 | J01RA05 | J01RA09 | S01AE01 | S01AE05 | S02AA16
SMILES: CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 78
Group description: Levofloxacin: 500mg, PO, once daily for 3 months
Eligibility criteria:
Inclusion Criteria:

a primary or repeat kidney transplant recipient (deceased or living donor)
age greater or equal to 18 years

Exclusion Criteria:

Unable to provide informed consent
Greater than 5 days post-transplantation
BK virus nephropathy with a previous transplant
History of allergic reaction to any quinolone antibiotic
History of quinolone associated tendonitis or tendon rupture
Corrected QT interval prolongation on EKG as defined by Al-Khatib
Concomitant use of medication known to prolong the QT interval such as class IA antiarrhythmic drugs (e.g. quinidine, procainamide, disopyramide), class III antiarrhythmic drugs (e.g. amiodarone, sotalol), azole antifungals (e.g. fluconazole) or macrolide antibiotics (e.g. erythromycin)
Pregnant or breastfeeding as safety of levofloxacin not established
Requires quinolone antibiotic for more than 14 days (e.g. for UTI prophylaxis)
Recipient of a multi-organ transplant (e.g. kidney-pancreas)
Currently enrolled in another interventional trial
Previously enrolled in this study
History of rhabdomyolysis
Significant allergic reaction to ≥ 3 classes of antibiotics as these patients may have no other option other than quinolones for routine infection.
Intervention: Econazole Nitrate
Trial phase: Phase 3
SMILES: Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1.O=[N+]([O-])O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 130
Group description: Study medication
Eligibility criteria:
Inclusion Criteria:

Be at least 12 years of age and of either sex.
Have a clinical diagnosis of interdigital tinea pedis involving at least2 web spaces in total which extends no more than approximately 1 inch proximal to the web spaces or metatarsophalangeal joints with at least i) moderate scaling and ii) mild erythema defined as a Grade 2 and Grade 1, respectively on the Grading of Signs and Symptoms at baseline.
Be willing and able to give informed consent/assent or have their parent/guardian do so, if applicable.
Be willing and able to use the assigned study medication as directed and to commit to all follow-up visits for the duration of the study.
Have microscopic evidence (positive KOH) of the presence of fungi. Evaluable subjects must have a positive KOH and a fungal culture positive for a dermatophyte in the skin scrapings taken at the Baseline Visit. Subjects with a positive KOH may be entered into the study pending the results of the fungal culture.
Be in good health and free of any disease or physical condition which might, in the Investigator's opinion, expose the subject to an unacceptable risk by study participation.
Females must be non-pregnant (confirmed by a negative urine pregnancy test at baseline), non-lactating and not intending to become pregnant during the course of the study.

Exclusion Criteria:

Is pregnant, nursing or planning a pregnancy during the study.
Has used topical antifungals or topical corticosteroids on the feet within 30 days prior to the start of the study.
Has received systemic antifungal therapy within 12 weeks prior to the start of the study medication.
Has used systemic antibacterials or systemic corticosteroids within 30 days prior to the start of the study. Systemic corticosteroids do not include intranasal, inhaled, and ophthalmic corticosteroids used for the management of allergies, pulmonary disorders or other conditions.
Has a history of uncontrolled diabetes mellitus or is immunocompromised (due to disease, e.g., HIV, or medications).
Has concurrent tinea infection e.g. tinea versicolor, tinea cruris, moccasin-type tinea pedis, etc. (in the opinion of the Investigator).
Onychomycosis, involving ≥ 20% of the area of either great toenail or involvement of more than five toenails in total.
Has any other skin disease which might interfere with the evaluation of tinea pedis.
Is currently enrolled in an investigational drug or device study.
Has received an investigational drug or treatment with an investigational device within 30 days prior to entering this study.
Is unreliable, including subjects with a history of drug or alcohol abuse.
Has known hypersensitivity to any of the components of the study medications.
Intervention: Acetylcysteine
Trial phase: Phase 2
ATC code: R05CB01 | S01XA08 | V03AB23
SMILES: CC(=O)N[C@@H](CS)C(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 31
Group description: N-Acetyl cysteine effervescent tablets in water 2 in am and 1 in pm for 28 weeks

n-acetylcysteine: 900 mg effervescent PharmaNAC tablet in water or juice: two tablets in the AM, one tablet in PM
Eligibility criteria:
Inclusion Criteria:

Capacity to provide informed consent
DSM IV TR diagnosis of schizophrenia, schizophreniform, schizoaffective
Psychiatric and medical stability
Prescribing clinician's premission to participate, assurance of medical stability
Having met threshold criteria for psychosis on CAARMS (Comprehensive Assessment of at Risk Mental States Scale) Psychosis subscale
Up to 12 months of antipsychotic treatment

Exclusion Criteria:

Severe medical comorbidities
Previous cerebral trauma
Substance induced psychosis or organic psychosis
Mental retardation
NAC allergy
Pregnancy, females and males planning pregnancy
Treatment with antioxidants
Insufficient command of English
Intervention: Carvedilol
Trial phase: Phase 4
ATC code: C07AG02 | C07FX06
SMILES: COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 14
Group description: Carvedilol is a is a beta-blocker. Beta-blockers are generally used to reduce the workload on the heart and help it to beat more regularly.

Carvedilol: target dose of 25 mg daily which is half the maximum dose used in clinical practice
Eligibility criteria:
Inclusion Criteria:

Diagnosis of AD by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria
Mini-Mental State Exam (MMSE) 16-26. This range corresponds roughly to "mild" AD as rated by CDR below, and provides a rapid test for efficient screening of potential participants.
Clinical Dementia Rating (CDR) < 1 (mild dementia). This corresponds with "early" AD. Participants will be eligible if they have AD diagnosis and CDR of 0.5 or 1.0. The category of CDR 0.5 AD is particularly important to include as these participants are in the earliest stage that can be diagnosed as dementia (as opposed to mild cognitive impairment) and thus are in the "earliest" clinical stage of AD.
Patients will be allowed to remain on current FDA-approved Alzheimer's treatments including cholinesterase inhibitors and memantine, so long as the dose has been stable for >= 3 months. These medications lack any notable effects on amyloid synthesis or metabolism and thus there is no reason to exclude them. The rationale behind requiring a stable dose is so that change in the trial can be attributed to the study intervention rather than recent changes of other medications affecting cognition.
Patients will be allowed to remain on antidepressant and antipsychotics medications so long as the dose has been stable for >= 3 months. The rationale is the same as above.
Knowledgeable informant available for all study visits. This is standard practice in AD research because many standard instruments and questionnaires in this trial require a knowledgeable informant.

Exclusion criteria

Evidence of non-AD dementias including Huntington's disease, Parkinson's disease, or frontotemporal dementia.

2.Current Diagnostic and Statistical Manual Diploma in Social Medicine (DSM)-IV Axis I diagnoses other than dementia, including major depression, bipolar disorder, schizophrenia, anxiety disorders, alcohol abuse, or other substance abuse. These diagnoses would merit their own treatment plans and changes in these conditions could significantly affect cognitive and functional outcomes, confounding our efforts to study the efficacy of the study intervention.

Any clinically significant medical condition that could interfere with the subject's ability to safely participate in the study or to be followed.
Current use of Beta-blocking agents.
Contraindications to use of Beta-blocking agents, to be determined in consultation with the patient's primary care physician or (if appropriate) cardiologist.
Clinically significant hepatic or renal insufficiency.
Intervention: Ladostigil Tartrate
Trial phase: Phase 2
SMILES: C#CCNC1CCc2ccc(OC(=O)N(C)CC)cc21.C#CCNC1CCc2ccc(OC(=O)N(C)CC)cc21.O=C(O)C(O)C(O)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 100
Group description: Ladostigil capsules 80 mg

ladostigil hemitartrate: Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage.
Eligibility criteria:
Inclusion Criteria:

AD diagnosis according to NINCDS-ADRDA criteria
Mild to moderate AD according to MMSE 14-24 inclusive
MRI or CT assessment within 6 months before baseline, corroborating the clinical diagnosis and excluding other potential causes of dementia especially cerebrovascular lesions
Absence of major depressive disease according to CSDD of less than or equal to 18
Modified Hachinski Ischemic Scale equal to or below 4
Education for eight or more years
Previous decline in cognition for more than six months as documented in patient medical records
A caregiver available and living in the same household or interacting with the patient daily and available if necessary to assure administration of investigational product
Patients living at home or nursing home setting without continuous nursing care
General health status acceptable for participation in a 12-month clinical trial and ability to swallow oral medication
No history of treatment with rivastigmine
For patients with either donepezil or galantamine anti-cholinesterase inhibitor treatment prescribed, stopped treatment four weeks prior to screening
For patients with memantine treatment prescribed, stopped treatment four weeks prior to screening

Exclusion Criteria:

Other primary degenerative dementias (e.g. dementia with Lewy bodies, fronto-temporal dementia, Huntington's disease, Jacob-Creutzfeldt disease)
Other neurodegenerative conditions (Parkinson's disease. amyotrophic lateral sclerosis, etc)
Other central nervous system diseases (severe head trauma, tumors, subdural hematoma, etc)
A current DSM-IV diagnosis of active major depression, schizophrenia or bipolar disorder
Seizure disorders
Other infectious, metabolic or systemic diseases affecting central nervous system (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency, serum electrolytes out of normal range, juvenile onset diabetes mellitus, etc)
Clinically significant, advanced or unstable disease that may interfere with primary or secondary variable evaluations
Other unstable, chronic or clinically significant medical conditions involving major organs like kidney, liver, lungs and heart/vasculature
Hospitalization or change of chronic concomitant medications one month prior to screening or during screening period
Intervention: Ladostigil Tartrate
Trial phase: Phase 2
SMILES: C#CCNC1CCc2ccc(OC(=O)N(C)CC)cc21.C#CCNC1CCc2ccc(OC(=O)N(C)CC)cc21.O=C(O)C(O)C(O)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 98
Group description: Placebo capsules

ladostigil hemitartrate: Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage.
Eligibility criteria:
Inclusion Criteria:

AD diagnosis according to NINCDS-ADRDA criteria
Mild to moderate AD according to MMSE 14-24 inclusive
MRI or CT assessment within 6 months before baseline, corroborating the clinical diagnosis and excluding other potential causes of dementia especially cerebrovascular lesions
Absence of major depressive disease according to CSDD of less than or equal to 18
Modified Hachinski Ischemic Scale equal to or below 4
Education for eight or more years
Previous decline in cognition for more than six months as documented in patient medical records
A caregiver available and living in the same household or interacting with the patient daily and available if necessary to assure administration of investigational product
Patients living at home or nursing home setting without continuous nursing care
General health status acceptable for participation in a 12-month clinical trial and ability to swallow oral medication
No history of treatment with rivastigmine
For patients with either donepezil or galantamine anti-cholinesterase inhibitor treatment prescribed, stopped treatment four weeks prior to screening
For patients with memantine treatment prescribed, stopped treatment four weeks prior to screening

Exclusion Criteria:

Other primary degenerative dementias (e.g. dementia with Lewy bodies, fronto-temporal dementia, Huntington's disease, Jacob-Creutzfeldt disease)
Other neurodegenerative conditions (Parkinson's disease. amyotrophic lateral sclerosis, etc)
Other central nervous system diseases (severe head trauma, tumors, subdural hematoma, etc)
A current DSM-IV diagnosis of active major depression, schizophrenia or bipolar disorder
Seizure disorders
Other infectious, metabolic or systemic diseases affecting central nervous system (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency, serum electrolytes out of normal range, juvenile onset diabetes mellitus, etc)
Clinically significant, advanced or unstable disease that may interfere with primary or secondary variable evaluations
Other unstable, chronic or clinically significant medical conditions involving major organs like kidney, liver, lungs and heart/vasculature
Hospitalization or change of chronic concomitant medications one month prior to screening or during screening period
Intervention: Cholecalciferol
Trial phase: Phase 2
ATC code: A11CC05 | A11CC55 | M05BB03 | M05BB04 | M05BB05 | M05BB07 | M05BB08 | M05BB09 | M05BX53
SMILES: [H][C@@]12CC[C@]([H])([C@H](C)CCCC(C)C)[C@@]1(C)CCC/C2=C\C=C1\C[C@@H](O)CCC1=C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 11
Group description: Participants in this group were assigned to receive weekly oral vitamin D drops using a weight-based calculated dosage for six months.

.
Eligibility criteria:
Inclusion Criteria:

Serum 25(OH)D<20ng/ml
Insulin Resistant based on HOMA-IR score of >3
Able and willing to provide informed consent
BMI 20-35

Exclusion Criteria:

HIV/AIDS
History of any cancer
Sarcoidosis
Alcohol or substance abuse
Cushing's syndrome
Primary hyperparathyroidism
Nephrolithiasis
Pregnancy or breastfeeding
Regular visits to a tanning salon
Hypercalcemia or hypocalcemia
Untreated or uncontrolled hypertension
Any chronic illness requiring medication, other than arthritis, hypertension and hyperlipidemia
Intervention: Resveratrol
Trial phase: Phase 2
SMILES: Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 12
Group description: Each participant received a supply of resveratrol (1,000mg) twice daily for 28 days.
Eligibility criteria:
Inclusion Criteria:

BMI: 26-35
Non-smoker
Normal screening labs (CMC, chemistry, LFTs PT/PTT)
No CAD
Good IV access

Exclusion Criteria:

High cholesterol
<4 week history of participation in another drug trial
Severe hypertension
Heart disease
Liver disease of liver abnormalities
Cerebrovascular disease, i.e. stroke
CVD
Seizures
Bleeding disorders
Muscle disease
Cancer
HIV
Hepatitis (all types)
Mentally disabled persons
Pregnant women
Allergies to Novocaine, Lidocaine, Benzocaine

Subjects on the following medications:

Anticoagulant and antiplatelet drugs
Anti-epileptic drugs
Mexiletene
Quinidine
Cyclosporine
Tacrolimus
HIV protease inhibitors
Intervention: Melatonin
Trial phase: Phase 2 | Phase 3
ATC code: N05CH01
SMILES: COc1ccc2[nH]cc(CCNC(C)=O)c2c1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 27
Group description: 6 mg oral melatonin daily
Eligibility criteria:
Inclusion Criteria:

Women, age 30-75, with breast cancer who are admitted for a lumpectomy or mastectomy at Herlev Hospital
ASA score I-III
No sign of depression measured my Major Depression Inventory (MDI)
Not pregnant

Exclusion Criteria:

Neoadjuvant chemotherapy
Treatment with SSRI, Warfarin or other anticoagulants (except 75 mg ASA daily), MAO inhibitors or calcium blockers
Rotor or Dubin-Johnson syndrome
Epilepsy
Known allergic reaction to melatonin
Known and treated sleep apnea
Diabetes Mellitus - insulin treated
Ongoing or previous medically treated depression or bipolar disorder
Known autoimmune diseases - systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and sclerose
Incompensated liver cirrhosis
Severe kidney disease
Previous or current cancer
Known medically treated sleep-disorder (insomnia, restless legs etc)
Shift-work and night-work
Daily alcohol intake of more than 5 units
Pre-operative treatment with psychopharmacological drugs, opioids or anxiolytics (including all sleeping pills)
Predicted bad compliance
Pregnant or breast-feeding
Pre-operative Mini Mental State Evaluation (MMSE) score less than 24
Intervention: Sapropterin
Trial phase: Phase 2
ATC code: A16AX07
SMILES: CC(O)C(O)C1CNc2nc(N)[nH]c(=O)c2N1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 18
Group description: Male subjects with hypertension and chronic kidney disease stage 2 or 3 received Tetrahydrobiopterin (BH4) 200 mg twice daily and folic acid 1 mg daily
Eligibility criteria:
Inclusion Criteria:

chronic kidney disease (CKD) stages I, II, and III and do not regularly exercise

1. CKD Stages I, II, and III will be defined as reduction in estimated glomerular filtration rate (eGFR) to 30-59 cc/minute as calculated by the Modification of Diet in Renal Disease (MDRD) equation, or an eGFR>60 cc/minute with proteinuria greater than 500 mg/g of Creatinine or 500 mg per 24 hours.

willing and able to cooperate with the protocol
CKD patients must have stable renal function (no greater than a 20% reduction in eGFR over the prior 3 months)
controls will be matched for age, gender, race, and hypertensive status.

Exclusion Criteria:

severe CKD (eGFR<30 cc/minute)
drug or alcohol abuse
diabetes
any serious systemic disease that might influence survival
severe anemia with hgb level <10 g/dL
clinical evidence of congestive heart failure or ejection fraction below 35%
any history of past myocardial infarction or cerebrovascular accident
symptomatic heart disease determined by electrocardiogram, stress test, and/or history
treatment with central alpha agonists
uncontrolled hypertension with BP greater than 160/90 mm Hg
low blood pressure with BP less than 110/60
history of nephrolithiasis
pregnancy or plans to become pregnant
treatment with vitamin C within the past 3 months
hepatic enzyme concentrations greater than 2 times the upper limit of normal
HIV infection
surgery within the past 3 months
previous treatment with BH4
known hypersensitivity to BH4
any condition that places the participant at high risk of poor adherence or poor follow-up
patients must be willing to use an acceptable method of contraception if of childbearing age